181 related articles for article (PubMed ID: 25837487)
1. In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells.
Leikam C; Hufnagel AL; Otto C; Murphy DJ; Mühling B; Kneitz S; Nanda I; Schmid M; Wagner TU; Haferkamp S; Bröcker EB; Schartl M; Meierjohann S
Cell Death Dis; 2015 Apr; 6(4):e1711. PubMed ID: 25837487
[TBL] [Abstract][Full Text] [Related]
2. Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence.
Leikam C; Hufnagel A; Schartl M; Meierjohann S
Oncogene; 2008 Nov; 27(56):7070-82. PubMed ID: 18806824
[TBL] [Abstract][Full Text] [Related]
3. BRAFE600-associated senescence-like cell cycle arrest of human naevi.
Michaloglou C; Vredeveld LC; Soengas MS; Denoyelle C; Kuilman T; van der Horst CM; Majoor DM; Shay JW; Mooi WJ; Peeper DS
Nature; 2005 Aug; 436(7051):720-4. PubMed ID: 16079850
[TBL] [Abstract][Full Text] [Related]
4. Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function.
van Tuyn J; Jaber-Hijazi F; MacKenzie D; Cole JJ; Mann E; Pawlikowski JS; Rai TS; Nelson DM; McBryan T; Ivanov A; Blyth K; Wu H; Milling S; Adams PD
J Invest Dermatol; 2017 Oct; 137(10):2197-2207. PubMed ID: 28647344
[TBL] [Abstract][Full Text] [Related]
5. Oncogene-induced cellular senescence.
Chandeck C; Mooi WJ
Adv Anat Pathol; 2010 Jan; 17(1):42-8. PubMed ID: 20032638
[TBL] [Abstract][Full Text] [Related]
6. Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.
Haferkamp S; Scurr LL; Becker TM; Frausto M; Kefford RF; Rizos H
J Invest Dermatol; 2009 Aug; 129(8):1983-91. PubMed ID: 19212341
[TBL] [Abstract][Full Text] [Related]
7. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
8. Cystathionase mediates senescence evasion in melanocytes and melanoma cells.
Leikam C; Hufnagel A; Walz S; Kneitz S; Fekete A; Müller MJ; Eilers M; Schartl M; Meierjohann S
Oncogene; 2014 Feb; 33(6):771-82. PubMed ID: 23353821
[TBL] [Abstract][Full Text] [Related]
9. Effect of cellular senescence on the growth of HER2-positive breast cancers.
Zacarias-Fluck MF; Morancho B; Vicario R; Luque Garcia A; Escorihuela M; Villanueva J; Rubio IT; Arribas J
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25972601
[TBL] [Abstract][Full Text] [Related]
10. Wnt signaling potentiates nevogenesis.
Pawlikowski JS; McBryan T; van Tuyn J; Drotar ME; Hewitt RN; Maier AB; King A; Blyth K; Wu H; Adams PD
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16009-14. PubMed ID: 24043806
[TBL] [Abstract][Full Text] [Related]
11. Cellular senescence in vivo: a barrier to tumorigenesis.
Prieur A; Peeper DS
Curr Opin Cell Biol; 2008 Apr; 20(2):150-5. PubMed ID: 18353625
[TBL] [Abstract][Full Text] [Related]
12. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
Shin J; Yang J; Lee JC; Baek KH
Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
[TBL] [Abstract][Full Text] [Related]
13. The Immortal Senescence.
Bianchi-Smiraglia A; Lipchick BC; Nikiforov MA
Methods Mol Biol; 2017; 1534():1-15. PubMed ID: 27812863
[TBL] [Abstract][Full Text] [Related]
14. Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1).
Nieto M; Barradas M; Criado LM; Flores JM; Serrano M; Llano E
Oncogene; 2007 Mar; 26(12):1673-80. PubMed ID: 16964279
[TBL] [Abstract][Full Text] [Related]
15. Role of melanoma inhibitory activity in melanocyte senescence.
Feuerer L; Lamm S; Henz I; Kappelmann-Fenzl M; Haferkamp S; Meierjohann S; Hellerbrand C; Kuphal S; Bosserhoff AK
Pigment Cell Melanoma Res; 2019 Nov; 32(6):777-791. PubMed ID: 31172672
[TBL] [Abstract][Full Text] [Related]
16. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.
Di Micco R; Fumagalli M; Cicalese A; Piccinin S; Gasparini P; Luise C; Schurra C; Garre' M; Nuciforo PG; Bensimon A; Maestro R; Pelicci PG; d'Adda di Fagagna F
Nature; 2006 Nov; 444(7119):638-42. PubMed ID: 17136094
[TBL] [Abstract][Full Text] [Related]
17. TGF-β may control the switch between tumorigenic growth and "stem cell/mesenchymal" potentially drug-resistant states.
Bordelon JR; Grichnik JM
Dermatol Ther; 2015; 28(3):177-8. PubMed ID: 25649199
[No Abstract] [Full Text] [Related]
18. Quiescent melanocytes form primary cilia.
Le Coz M; Benmerah A; Larue L
Exp Dermatol; 2014 Jun; 23(6):426-7. PubMed ID: 24758532
[TBL] [Abstract][Full Text] [Related]
19. Oncogene-induced senescence: a double edged sword in cancer.
Liu XL; Ding J; Meng LH
Acta Pharmacol Sin; 2018 Oct; 39(10):1553-1558. PubMed ID: 29620049
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells versus phenotype-switching in melanoma.
Hoek KS; Goding CR
Pigment Cell Melanoma Res; 2010 Dec; 23(6):746-59. PubMed ID: 20726948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
